Scan to Download ios&Android APP

Trade Valneva SE - VLA CFD

17.34
2.79%
0.13
Low: 9.57
High: 9.97
Market Trading Hours* (UTC) Opens on Tuesday at 07:01

Mon - Fri: 07:01 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0206%
Short position overnight fee -0.0238%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 20%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 9.68
Open* 9.64
Day's Range* 9.57 - 9.57
1-Year Change* -3.21%
Volume N/A
Average Vol. (3m) 18.5727
52 wk Range N/A
Market Cap 1141.87
P/E Ratio N/A
Shares Outstanding 107727000
Revenue 346.718
EPS -0.72064
Dividend (Yield %) N/A
Beta 0.49167
Next Earnings Date Aug 11, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 5, 2022 9.68 0.05 0.52% 9.63 9.87 9.51
Aug 4, 2022 9.69 0.07 0.73% 9.62 9.89 9.53
Aug 3, 2022 9.58 0.24 2.57% 9.34 9.74 9.32
Aug 2, 2022 9.63 -0.04 -0.41% 9.67 9.79 9.49
Aug 1, 2022 9.71 0.16 1.68% 9.55 9.83 9.49
Jul 29, 2022 9.62 -0.27 -2.73% 9.89 9.94 9.51
Jul 28, 2022 9.92 0.03 0.30% 9.89 10.07 9.79
Jul 27, 2022 9.87 -0.16 -1.60% 10.03 10.19 9.79
Jul 26, 2022 9.89 0.26 2.70% 9.63 9.95 9.44
Jul 25, 2022 9.71 -0.07 -0.72% 9.78 10.04 9.59
Jul 22, 2022 9.79 -0.16 -1.61% 9.95 10.44 9.76
Jul 21, 2022 9.99 -0.46 -4.40% 10.45 10.45 8.96
Jul 20, 2022 10.47 0.34 3.36% 10.13 10.57 10.05
Jul 19, 2022 10.25 0.35 3.54% 9.90 10.32 9.81
Jul 18, 2022 9.95 -0.10 -1.00% 10.05 10.35 9.92
Jul 15, 2022 10.07 0.22 2.23% 9.85 10.15 9.72
Jul 14, 2022 9.95 0.02 0.20% 9.93 10.19 9.81
Jul 13, 2022 10.19 0.13 1.29% 10.06 10.32 9.76
Jul 12, 2022 9.99 -0.21 -2.06% 10.20 10.42 9.90
Jul 11, 2022 10.36 0.24 2.37% 10.12 10.95 10.10

Valneva SE Events

Time (UTC) Country Event
Monday, August 8, 2022
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 94.062 105.291 113.035 126.196 110.321 348.086
Revenue 94.062 105.291 113.035 126.196 110.321 348.086
Cost of Revenue, Total 43.076 45.979 44.448 49.968 46.902 182.22
Gross Profit 50.986 59.312 68.587 76.228 63.419 165.866
Total Operating Expense 136.63 109.245 106.774 127.007 165.441 409.476
Selling/General/Admin. Expenses, Total 31.196 33.422 37.84 42.277 45.171 70.761
Research & Development 24.589 22.156 24.291 36.783 61.354 168.583
Depreciation / Amortization 41.246 12.142 4.331 4.464 4.9 5.4
Unusual Expense (Income) 0.124 0 0.007 0.092 26.41 5.742
Other Operating Expenses, Total -3.601 -4.454 -4.143 -6.577 -19.296 -23.23
Operating Income -42.568 -3.954 6.261 -0.811 -55.12 -61.39
Interest Income (Expense), Net Non-Operating -6.26 -8.606 -2.909 -0.059 -10.182 -8.281
Other, Net 0 -0.001 -0.308
Net Income Before Taxes -48.828 -12.56 3.351 -0.87 -65.302 -69.979
Net Income After Taxes -49.184 -11.482 3.263 -1.744 -64.393 -73.425
Net Income Before Extra. Items -49.184 -11.482 3.263 -1.744 -64.393 -73.425
Net Income -49.184 -11.482 3.263 -1.744 -64.393 -73.425
Income Available to Common Excl. Extra. Items -49.184 -11.482 3.264 -1.744 -64.393 -73.425
Income Available to Common Incl. Extra. Items -49.184 -11.482 3.264 -1.744 -64.393 -73.425
Diluted Net Income -49.184 -11.482 3.264 -1.744 -64.393 -73.425
Diluted Weighted Average Shares 74.6589 77.4492 81.6002 91.7443 90.7572 97.6193
Diluted EPS Excluding Extraordinary Items -0.65878 -0.14825 0.04 -0.01901 -0.70951 -0.75216
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.6577 -0.14825 0.04008 -0.01836 -0.51936 -0.71392
Total Adjustments to Net Income 0.001
Dilution Adjustment 0
Mar 2021 Jun 2021 Dec 2021 Mar 2022
Total revenue 23.215 47.502 300.584 21.847
Revenue 23.215 47.502 300.584 21.847
Cost of Revenue, Total 14.65 34.778 153.142 13.86
Gross Profit 8.565 12.724 147.442 7.987
Total Operating Expense 54.353 133.674 275.802 40.269
Selling/General/Admin. Expenses, Total 14.951 30.68 40.781 7.804
Research & Development 27.732 78.737 94.546 20.689
Other Operating Expenses, Total -2.98 -10.542 -12.688 -2.084
Operating Income -31.138 -86.172 24.782 -18.422
Interest Income (Expense), Net Non-Operating 3.069 0.441 -8.722 -7.117
Other, Net -0.001 0.001 -0.309
Net Income Before Taxes -28.07 -85.73 15.751 -25.539
Net Income After Taxes -27.702 -86.398 12.973 -26.041
Net Income Before Extra. Items -27.702 -86.398 12.973 -26.041
Net Income -27.702 -86.398 12.973 -26.041
Income Available to Common Excl. Extra. Items -27.702 -86.399 12.974 -26.041
Income Available to Common Incl. Extra. Items -27.702 -86.399 12.974 -26.041
Diluted Net Income -27.702 -86.399 12.974 -26.041
Diluted Weighted Average Shares 92.34 94.944 100.295 108.504
Diluted EPS Excluding Extraordinary Items -0.3 -0.91 0.12936 -0.24
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.3 -0.90986 0.12953 -0.24
Unusual Expense (Income) 0.021 0.021
Total Adjustments to Net Income -0.001 0.001
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 91.197 83.448 125.972 129.162 308.427 585.832
Cash and Short Term Investments 35.267 33.545 77.084 64.439 204.394 346.642
Cash 34.266 32.541 57.085 39.439 173.109 346.642
Cash & Equivalents -0.001 -0.001
Short Term Investments 1.002 1.004 20 25 31.285
Total Receivables, Net 16.912 17.622 11.259 24.03 19.232 44.013
Accounts Receivable - Trade, Net 16.912 17.622 11.259 24.03 19.232 44.013
Total Inventory 22.701 19.931 22.727 25.772 26.933 124.098
Other Current Assets, Total 16.317 12.35 14.902 14.921 57.868 71.079
Total Assets 206.883 189.343 229.907 264.723 449.164 817.352
Property/Plant/Equipment, Total - Net 39.039 38.374 37.997 69.337 78.153 173.83
Property/Plant/Equipment, Total - Gross 74.782 72.646 75.012 100.5 111.31 215.283
Accumulated Depreciation, Total -35.742 -34.273 -37.015 -31.163 -33.156 -41.453
Intangibles, Net 58.959 48.468 44.891 41.813 35.409 32.7
Other Long Term Assets, Total 17.688 19.053 19.925 22.148 25.045 22.866
Total Current Liabilities 38.891 37.674 42.944 41.3 175.87 368.979
Accounts Payable 2.554 5.258 9.175 8.868 24.898 16.035
Accrued Expenses 12.378 11.799 12.793 18.323 24.479 69.333
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 20.959 17.399 17.529 4.307 9.684 10.242
Other Current Liabilities, Total 3 3.218 3.447 9.802 116.809 273.369
Total Liabilities 106.831 96.674 86.72 129.57 371.742 646.771
Total Long Term Debt 61.544 54.097 40.07 80.909 95.767 104.413
Long Term Debt 34.024 27.435 14.272 24.317 46.375 50.726
Capital Lease Obligations 27.52 26.662 25.798 56.592 49.392 53.687
Deferred Income Tax 0.065 0.065 0.412 1.29
Other Liabilities, Total 6.331 4.838 3.706 7.361 99.693 172.089
Total Equity 100.052 92.669 143.187 135.153 77.422 170.581
Common Stock 11.638 11.638 13.638 13.642 13.646 15.786
Additional Paid-In Capital 252.937 252.934 297.72 297.732 244.984 409.258
Retained Earnings (Accumulated Deficit) -156.038 -166.686 -161.559 -170.272 -177.835 -248.671
Treasury Stock - Common -1.006 -1.11 -1.133 -1.112 -0.898 -0.645
Other Equity, Total -7.479 -4.107 -5.479 -4.837 -2.475 -5.147
Total Liabilities & Shareholders’ Equity 206.883 189.343 229.907 264.723 449.164 817.352
Total Common Shares Outstanding 77.4595 77.396 90.7935 90.8195 90.8242 105.115
Total Preferred Shares Outstanding 17.8367 17.8367 17.8367 17.8367 17.8367 17.8367
Long Term Investments 1.122 2.263 2.13 2.124
Mar 2021 Jun 2021 Dec 2021 Mar 2022
Total Current Assets 416.981 561.962 585.832 545.021
Cash and Short Term Investments 235.913 329.724 346.642 311.264
Cash & Equivalents 235.913 0.001 311.264
Total Receivables, Net 25.1 18.007 44.013 25.061
Accounts Receivable - Trade, Net 25.1 18.007 44.013 25.061
Total Inventory 97.4 125.664 124.098 139.725
Other Current Assets, Total 58.568 88.567 71.079 68.971
Total Assets 574.112 745.107 817.352 777.711
Property/Plant/Equipment, Total - Net 93.622 123.028 173.83 175.98
Intangibles, Net 35.156 34.424 32.7 31.765
Long Term Investments 2.111 2.039 2.124 2.124
Other Long Term Assets, Total 26.242 23.654 22.866 22.821
Total Current Liabilities 320.357 456.917 368.979 363.257
Payable/Accrued 60.878 71.502 68.119 66.268
Accrued Expenses 11.779 12.265 17.249 19.838
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 8.548 10.168 10.242 14.852
Other Current Liabilities, Total 239.152 362.982 273.369 262.299
Total Liabilities 521.757 668.037 646.771 629.305
Total Long Term Debt 97.461 101.318 104.413 100.668
Long Term Debt 48.868 47.402 50.726 48.005
Capital Lease Obligations 48.593 53.916 53.687 52.663
Deferred Income Tax 0.503 0.59 1.29 1.28
Other Liabilities, Total 103.436 109.212 172.089 164.1
Total Equity 52.355 77.07 170.581 148.406
Common Stock 13.765 14.986 15.786 16.17
Additional Paid-In Capital 247.074 328.688 409.258 412.799
Retained Earnings (Accumulated Deficit) -208.483 -266.604 -254.462 -280.563
Other Equity, Total -0.001 -0.001
Total Liabilities & Shareholders’ Equity 574.112 745.107 817.352 777.711
Total Common Shares Outstanding 91.6379 99.7626 105.115 107.727
Total Preferred Shares Outstanding 17.8367 17.8367 17.8367 17.8367
Cash 329.723 346.642
Short Term Investments 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -49.184 -11.482 3.264 -1.744 -64.393 -73.425
Cash From Operating Activities 6.505 12.829 16.306 5.529 137.779 76.945
Cash From Operating Activities 11.269 11.141 6.828 8.532 9.799 14.281
Non-Cash Items 41.92 9.631 3.534 7.769 116.613 101.55
Cash Taxes Paid 0.532 0.66 1.273 2.346 2.021 1.631
Cash Interest Paid 10.932 4.98 4.165 2.621 4.711 8.417
Changes in Working Capital 2.5 3.539 2.68 -9.028 75.76 34.539
Cash From Investing Activities 14.888 -4.06 -2.917 -10.685 -19.34 -93.116
Capital Expenditures -3.682 -4.038 -3.171 -10.884 -19.471 -93.171
Other Investing Cash Flow Items, Total 18.57 -0.022 0.254 0.199 0.131 0.055
Cash From Financing Activities -26.792 -10.438 30.945 -7.696 21.74 154.504
Financing Cash Flow Items -10.933 -4.98 -4.165 -2.621 -4.71 -8.417
Issuance (Retirement) of Stock, Net 7.473 -0.147 49.263 -2.463 0.29 166.823
Issuance (Retirement) of Debt, Net -23.332 -5.311 -14.153 -2.612 26.16 -3.902
Foreign Exchange Effects -1.241 -0.053 -0.795 0.207 -0.183 3.96
Net Change in Cash -6.64 -1.722 43.539 -12.645 139.996 142.293
Mar 2021 Jun 2021 Dec 2021 Mar 2022
Net income/Starting Line -27.702 -86.399 -73.425 -26.041
Cash From Operating Activities 47.602 84.289 76.945 -26.806
Non-Cash Items 6.232 10.901 101.55 -6.922
Cash Taxes Paid 1.296 1.313 1.631 0.318
Cash Interest Paid 3.396 3.718 8.417 1.909
Changes in Working Capital 69.072 153.686 34.539 6.157
Cash From Investing Activities -16.857 -39.902 -93.116 -9.447
Capital Expenditures -16.876 -39.934 -93.171 -9.461
Other Investing Cash Flow Items, Total 0.019 0.032 0.055 0.014
Cash From Financing Activities -1.55 78.743 154.504 0.982
Financing Cash Flow Items -3.395 -3.718 -8.417 -1.909
Issuance (Retirement) of Stock, Net 2.363 85.386 166.823 3.726
Issuance (Retirement) of Debt, Net -0.518 -2.925 -3.902 -0.835
Foreign Exchange Effects 2.324 2.242 3.96 -0.107
Net Change in Cash 31.519 125.372 142.293 -35.378
Cash From Operating Activities 6.101 14.281

Still looking for a broker you can trust?

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Valneva SE Company profile

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Financial summary

BRIEF: For the six months ended 30 June 2021, Valneva SE revenues decreased 1% to EUR47.5M. Net loss applicable to common stockholders increased from EUR25.6M to EUR86.4M. Revenues reflect Commercialized Vaccines segment decrease of 22% to EUR31.8M, Canada segment decrease of 75% to EUR2M, United Kingdom segment decrease of 75% to EUR1.1M, Europe excluding France segment decrease of 42% to EUR4.2M.

Equity composition

07/2010, Rights Issue, 2 new shares for every 5 shares held @ EUR 5.06 (Factor: 1.12817). 6/2013, Rights Issue, 5 new shares for every 13 shares held @ EUR2.65 (Factor: 1.11881). 1/2015, Rights Issue, 11 new shares for every 34 shares held @ EUR2.47 (Factor: 1.10896).

Industry: Biotechnology & Medical Research (NEC)

6 rue Alain Bombard
44800

Income statement

People Also Watch

Bitcoin to US Dollar

23,975.25 Price
+3.800% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 66.00

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading